Get to know our clinical trials

Trial of CLN-049 for the treatment of acute myeloid leukemia (AML) patients with measurable residual disease (MRD).

BY CONDUCTING THIS STUDY, WE HOPE TO UNDERSTAND: WHAT ARE THE SIDE EFFECTS OF CLN-049? WHAT IS THE HIGHEST DOSE OF CLN-049 THAT CAN BE GIVEN TO PATIENTS WITHOUT CAUSING SERIOUS SIDE EFFECTS? HOW DOES YOUR CANCER RESPOND TO CLN-049? HOW LONG DOES CLN-049 STAY IN YOUR BLOOD? HOW DOES CLN-049 AFFECT YOUR IMMUNE SYSTEM? THE CLN

Imagen de la Dra. Ana Alfonso Piérola, especialista en Hematología de la Clínica Universidad de Navarra. La Dra. Alfonso se dedica al estudio y tratamiento de los síndromes mielodisplásicos y las leucemias mieloblásticas agudas.
Dr. Ana Alfonso Piérola [SP] Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • PHASE I, OPEN-LABEL, DOSE-ESCALATION AND DOSE-ESCALATION STUDY OF CLN-049 FOR THE TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH MEASURABLE RESIDUAL DISEASE (MRD).
  • Code EudraCT: 2023-506572-27-00
  • Protocol number: CLN-049-002
  • Promoter: Cullinan MICA Corp.
  • Molecule/Drug: CLN-049

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION